11 research outputs found
Evaluation of groundwater geochemical characteristics and quality in the central and Northern Shaanxi Province, China
Cytotoxic effects of Mangifera indica L. kernel extract on human breast cancer (MCF-7 and MDA-MB-231 cell lines) and bioactive constituents in the crude extract
GIS-based evaluation and statistical determination of groundwater geochemistry for potential irrigation use in El Moghra, Egypt
The history, fungal biodiversity, conservation, and future perspectives for mycology in Egypt
Blood Vessels are Regulators of Growth, Diagnostic Markers and Therapeutic Targets in Prostate Cancer
Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives
Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies
Despite improvements in early detection and advances in treatment, patients with prostate cancer continue to die from their disease. Minimal residual disease after primary definitive treatment can lead to relapse and distant metastases, and increasing evidence suggests that circulating tumour cells (CTCs) and bone marrow-derived disseminated tumour cells (BM-DTCs) can offer clinically relevant biological insights into prostate cancer dissemination and metastasis. Using epithelial markers to accurately detect CTCs and BM-DTCs is associated with difficulties, and prostate-specific markers are needed for the detection of these cells using rare cell assays. Putative prostate-specific markers have been identified, and an optimized strategy for staining rare cancer cells from liquid biopsies using these markers is required. The ideal prostate-specific marker will be expressed on every CTC or BM-DTC throughout disease progression (giving high sensitivity) and will not be expressed on non-prostate-cancer cells in the sample (giving high specificity). Some markers might not be specific enough to the prostate to be used as individual markers of prostate cancer cells, whereas others could be truly prostate-specific and would make ideal markers for use in rare cell assays. The goal of future studies is to use sensitive and specific prostate markers to consistently and reliably identify rare cancer cells